ATE248190T1 - Chemoattraktion-auslösender faktor aus lymphozyten und dessen verwendungen - Google Patents

Chemoattraktion-auslösender faktor aus lymphozyten und dessen verwendungen

Info

Publication number
ATE248190T1
ATE248190T1 AT96918305T AT96918305T ATE248190T1 AT E248190 T1 ATE248190 T1 AT E248190T1 AT 96918305 T AT96918305 T AT 96918305T AT 96918305 T AT96918305 T AT 96918305T AT E248190 T1 ATE248190 T1 AT E248190T1
Authority
AT
Austria
Prior art keywords
triggering factor
chemoattraction
lymphocyte
lymphocyte chemoattraction
triggering
Prior art date
Application number
AT96918305T
Other languages
English (en)
Inventor
David M Center
William W Cruikshank
Hardy Kornfeld
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Application granted granted Critical
Publication of ATE248190T1 publication Critical patent/ATE248190T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5446—IL-16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96918305T 1995-06-07 1996-06-07 Chemoattraktion-auslösender faktor aus lymphozyten und dessen verwendungen ATE248190T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/480,156 US5807549A (en) 1993-05-21 1995-06-07 Lymphocyte chemoattractant factor and uses thereof
PCT/US1996/009422 WO1996040786A1 (en) 1995-06-07 1996-06-07 Lymphocyte chemoattractant factor and uses thereof

Publications (1)

Publication Number Publication Date
ATE248190T1 true ATE248190T1 (de) 2003-09-15

Family

ID=23906878

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96918305T ATE248190T1 (de) 1995-06-07 1996-06-07 Chemoattraktion-auslösender faktor aus lymphozyten und dessen verwendungen

Country Status (7)

Country Link
US (5) US5807549A (de)
EP (1) EP0832132B1 (de)
AT (1) ATE248190T1 (de)
CA (1) CA2223262A1 (de)
DE (1) DE69629688T2 (de)
ES (1) ES2205037T3 (de)
WO (1) WO1996040786A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1155700A3 (de) * 1993-05-21 2002-01-02 Research Corporation Technologies, Inc Chemoattraktion-auslösender Faktor aus Lymfozyten und dessen Verwendungen
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6699466B1 (en) * 1999-08-05 2004-03-02 Research Corporation Technologies, Inc. IL-16 antagonist peptides and DNA encoding the peptides
US7998681B2 (en) * 2000-10-06 2011-08-16 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Diagnosis and therapy of antibody-mediated inflammatory auto-immune disorders
EA200300473A1 (ru) * 2000-10-16 2003-08-28 Неофарм, Инк. Терапевтическая композиция на основе митоксантрона (варианты) и липидный препарат, способ его получения и способ лечения заболевания млекопитающего с его использованием
SI1704166T1 (sl) 2004-01-07 2015-06-30 Novartis Vaccines And Diagnostics, Inc. M-scf specifiäśno monoklonsko protitelo in uporabe le-tega
SE0403038D0 (sv) * 2004-12-14 2004-12-14 Tetra Laval Holdings & Finance Anordning och metod för försegling
EP2277916A3 (de) * 2005-07-28 2011-04-27 Novartis AG Verwendung von Antikörper zu M-CSF
EP1913027B1 (de) * 2005-07-28 2015-03-04 Novartis AG M-csf-spezifische monoklonale antikörper und anwendungen davon
WO2007053524A2 (en) * 2005-10-28 2007-05-10 The Florida International University Board Of Trustees Horse: human chimeric antibodies
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
BRPI0715332A2 (pt) 2006-08-04 2013-10-08 Novartis Ag Anticorpo, métodos de triar um anticorpo quanto ao domínio extracelular de uma proteína ephb3 útil para o tratamento de câncer, de alterar sistemicamente os anticorpos e triar um anticorpo quanto ao domínio extracelular de uma proteína ephb3 para o tratamento de câncer, de tratar um paciente que sofre de câncer, de alvejar uma célula tumoral que expressa epbh3, e de usar a célula hospedeira, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, composição farmacêutica, e kit.
NZ596834A (en) 2006-08-18 2013-06-28 Novartis Ag Prlr-specific antibody and uses thereof
WO2008039716A2 (en) * 2006-09-28 2008-04-03 Centocor Ortho Biotech Inc. Method for detecting il-16 activity and modulation of il-16 activity based on phosphorylated stat-6 proxy levels
EP2094305A4 (de) * 2006-10-27 2011-01-05 Centocor Ortho Biotech Inc Verfahren zur behandlung von lungenleiden und bleomycin-assoziierter lungenfibrose
EP2101816B1 (de) 2006-12-07 2013-08-14 Novartis AG Antagonistische antikörper gegen ephb3
TW201307390A (zh) * 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
MX2010008096A (es) 2008-01-25 2010-09-22 Amgen Inc Anticuerpos de ferroportina y metodos de uso.
EP2620448A1 (de) 2008-05-01 2013-07-31 Amgen Inc. Anti-hepcidin-antikörper und Verfahren zu ihrer Verwendung
US20110217259A1 (en) * 2010-03-03 2011-09-08 Djordje Atanackovic IL-16 as a target for diagnosis and therapy of hematological malignancies and solid tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486530A (en) * 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4745051A (en) * 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4844893A (en) * 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
ATE125305T1 (de) * 1989-01-23 1995-08-15 Abbott Lab Monoklonale antikörper von ratten gegen menschliche antigene und verfahren zu deren herstellung.
US4918077A (en) * 1989-01-25 1990-04-17 E. I. Du Pont De Nemours & Co., Inc. 3-phenyl-5,6-dihydrobenz(c)acridine-7-carboxylic acids and related compounds as cancer chemotherapeutic agents
US5514555A (en) * 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
EP1155700A3 (de) * 1993-05-21 2002-01-02 Research Corporation Technologies, Inc Chemoattraktion-auslösender Faktor aus Lymfozyten und dessen Verwendungen

Also Published As

Publication number Publication date
US5976522A (en) 1999-11-02
WO1996040786A1 (en) 1996-12-19
US5766866A (en) 1998-06-16
ES2205037T3 (es) 2004-05-01
EP0832132A1 (de) 1998-04-01
CA2223262A1 (en) 1996-12-19
DE69629688T2 (de) 2004-06-17
US5807549A (en) 1998-09-15
EP0832132B1 (de) 2003-08-27
US5869263A (en) 1999-02-09
DE69629688D1 (de) 2003-10-02
US5965120A (en) 1999-10-12

Similar Documents

Publication Publication Date Title
ATE248190T1 (de) Chemoattraktion-auslösender faktor aus lymphozyten und dessen verwendungen
SE9503925D0 (sv) Separationsmedium för IgG
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
DE69226431D1 (de) Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor
DE69319662D1 (de) Monoklonale Antikörper gegen GP130-Protein
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
DK0620854T3 (da) Ekspression og oprensning af rekombinant opløselig vævsfaktor
DE69631468T2 (de) Nachweis von antikörpern gegen bakterielle antigene durch fluoreszenz-polarisation
ATE282045T1 (de) Verbindungen und verfahren zur hemmung von wechselwirkung zwischen alpha-catenin und beta- catenin
ATE248859T1 (de) Metallion-ligand koordinationskomplexe, antikorper dagegen und tests die solche antikorper verwenden
FI964845A7 (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
DE69942668D1 (de) Humanisierter monoklonaler antikörper gegen von-willebrand faktor
ATE217086T1 (de) Herstellung von photoprotein konjugaten und verfahren zu ihrer verwendung
DE59508474D1 (de) RHEUMAFAKTOR-ENTSTÖRUNG MIT ANTI-Fd-ANTIKÖRPERN
DE69322783D1 (de) Monoklonale Antikörper gegen Glykoprotein P
ATE206140T1 (de) Polyklonaler antikörper gegen tryptase und reinigungsverfahren zur verwendung in einem immunoassay für menschliche tryptase
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DE3580382D1 (de) Monoklonale antikoerper gegen alpha-2 interferon und hybridomas, die solche antikoerper produzieren.
DK0580672T3 (da) Syntetisk CDw52-(CAMPATH-1)-peptidantigen
FI925321A0 (fi) Immunodiagnostiskt ledinflammationstest
ATE207935T1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
DE69024871D1 (de) Monoklonaler Antikörper gegen menschliches BCDF und Immuntestverfahren unter dessen Verwendung
ATE184315T1 (de) Neuartiges endothelzell-molekül, das die bindung von lymphozyten im menschen vermittelt
GR970300022T1 (en) Peptide capable of being recognised by antibodies recognising the C33 antigen of hepatitis C virus
RU94026276A (ru) Рецепторы интерлейкина-12 и антител

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0832132

Country of ref document: EP